- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04098874
Bupropion for the Prevention of Postpartum Smoking Relapse
February 19, 2024 updated by: University of Minnesota
This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum.
Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks post-randomization).
All participants will complete the same data collection procedures (e.g., biological sample collection for hormone and cotinine analysis and completion of validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52 post-randomization.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katherine Harrison, MPH
- Phone Number: 612-624-5377
- Email: harr0644@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Sharon Allen, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Ability to provide informed consent
- Age 18 to 40 years old
- Stable health
- 7-day point prevalence abstinence demonstrated at randomization
- Lifetime history of at least 100 cigarettes smoked
- Quit smoking during the current pregnancy
- Self-report of intention to remain abstinent after delivery ≥ 7 on a 10 point Likert-type scale
- Uncomplicated delivery
- Denies plans to become pregnant again during the trial.
- Full-term delivery ≥ 37 weeks gestation
- Home within 10 days of delivery
Exclusion Criteria:
- Current use of other forms of tobacco or nicotine (e-cigs, chew, snuff, etc.)
- Current use of cessation aids (e.g., varenicline, NRT)
- Current use of illicit drugs or alcohol dependence
- Current use of antidepressant medication
- Bipolar disorder, eating disorder, or psychotic disorder based on the Structured Clinical Interview
- Medications & conditions that may increase the risk of taking bupropion (e.g., current or history of pulmonary embolus, stroke, heart disease, kidney disease, glaucoma, diabetes, seizure disorder, traumatic head injury, use of medications metabolized by CYP2D6)
- Family history of seizures or seizure disorder
- Maternal use of medications that lower seizure threshold
- Newborn with an elevated risk of seizure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bupropion
Participants randomized to extended-release bupropion.
Once-daily
|
12 weeks postpartum of blinded study medication
|
Placebo Comparator: Placebo
Participants randomized to placebo.
Once-daily
|
12 weeks postpartum of blinded placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Point prevalence smoking abstinence
Time Frame: 24 weeks post randomization
|
7-day point prevalence abstinence
|
24 weeks post randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sharon Allen, MD, University of Minnesota
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2020
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
September 19, 2019
First Submitted That Met QC Criteria
September 19, 2019
First Posted (Actual)
September 23, 2019
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 19, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Recurrence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
Other Study ID Numbers
- FMCH-2019-28219
- R01DA047287 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Only de-identified data collected in this trial may be available to other researchers.
Requests for data will be considered on an individual basis by the study team.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Smoking Relapse
-
Yale UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedPostpartum Smoking RelapseUnited States
-
Semra YILMAZCompletedPostpartum Smoking RelapseTurkey
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Nabi...CompletedSmoking Behavior | Smoking Lapse Behavior | Smoking Relapse BehaviorNetherlands
-
University of MinnesotaEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingSmoking | Smoking Cessation | Smoking ReductionUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)Enrolling by invitationSmoking | Cigarette SmokingUnited States
-
NYU Langone HealthCompletedSmoking | Smoking CessationUnited States
-
University of TennesseeNational Heart, Lung, and Blood Institute (NHLBI); University of Minnesota; United...UnknownSmoking | Smoking CessationUnited States
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingTreatment | Cigarette Smoking | Smoking BehaviorsUnited States
-
University of NottinghamHer Majesty's Prison and Probation Service (HMPPS); Public Health England; Cancer... and other collaboratorsCompletedSmoking | Smoking Reduction | Electronic Cigarette UseUnited Kingdom
-
Loma Linda UniversityMarch of Dimes; American Academy of Pediatrics; Flight Attendant Medical Research...Completed
Clinical Trials on Bupropion Extended Release Oral Tablet
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Luye Pharma Group Ltd.CompletedMajor Depressive Disorder (MDD)China
-
Weill Medical College of Cornell UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedTolerance | Metformin Adverse ReactionUnited States
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
GlaxoSmithKlineTerminated
-
University of StellenboschUniversity of Rochester; Fogarty International Center of the National Institute...RecruitingMetabolic Syndrome | HIV SeropositivitySouth Africa
-
Terran Biosciences Australia Pty LtdRecruiting
-
Columbia UniversityBoston University; Johns Hopkins University; University of California, Berkeley; University of Miami and other collaboratorsRecruiting
-
Indiana Hemophilia &Thrombosis Center, Inc.Active, not recruitingPlasminogen Activator Inhibitor-1 Deficiency | Cardiac FibrosisUnited States
-
Methodist HealthcareCompletedRecipients of Liver TransplantUnited States